Use of fibrates in the metabolic syndrome:A review

作     者：Kate E Shipman Richard C Strange Sudarshan Ramachandran 

作者机构：Department of Clinical BiochemistryUni-versity Hospital Birmingham Institute for Science and Technology in MedicineKeele University Medical School Department of Clinical Bio-chemistryHeart of England NHS Foundation TrustGood Hope Hospital Department of Clinical Bio-chemistryUniversity Hospitals of North Midlands and Faculty of Health SciencesStaffordshire University 

出 版 物：《World Journal of Diabetes》 (世界糖尿病杂志（英文版）（电子版）)

年 卷 期：2016年第7卷第5期

页      面：74-88页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Fibrates Metabolic syndrome Paradoxical high density lipoprotein cholesterol decrease High density lipoprotein cholesterol Cardiovascular disease Peroxisome proliferator-activated receptor Randomised control trial Triglycerides 

摘      要：The use of fibrates in the treatment of dyslipidaemia has changed significantly over recent *** role appeared clear at the start of this *** Helsinki Heart Study and Veterans Affairs High-Density Cholesterol Intervention Trial suggested significant benefit,especially in patients with atherogenic ***,this clarity disintegrated following the negative outcomes reported by the Bezafibrate Infarction Prevention,Fenofibrate Intervention and Event Lowering in Diabetes and Action to Control Cardiovascular Risk in Diabetes randomised controlled *** this review we discuss these and other relevant trials and consider patient subgroups such as those with the metabolic syndrome and those needing treatment to prevent the microvascular complications associated with diabetes in whom fibrates may be *** also discuss observations from our group that may provide some explanation for the varying outcomes reported in large *** actions of fibrates in patients who are also on statins are interesting and appear to differ from those in patients not on *** this is key as statins are the primary lipid lowering agents and likely to occupy that position for the foreseeable *** also present other features of fibrate treatment we have observed in our clinical practice;changes in creatinine,liver function tests and the paradoxical high density lipoprotein *** purpose is to provide enough data for the reader to make objective decisions in their own clinical practice regarding fibrate use.